Biotech Values

[NP1986]

I think subgroup analyses in some of the anti-EGFR antibody trials have shown that KRAS mutant patients actually did worse in terms of PFS than the control group. I can't recall any specific trials though.

I think part of this may be due to do compensatory mechanisms, i.e. when you inhibit one pathway, you activate another one.

Or it could just be statistical noise.